Logo image of AZT.OL

ARCTICZYMES TECHNOLOGIES ASA (AZT.OL) Stock Fundamental Analysis

OSL:AZT - Euronext Oslo - NO0010014632 - Common Stock - Currency: NOK

17  +0.05 (+0.29%)

Fundamental Rating

5

Overall AZT gets a fundamental rating of 5 out of 10. We evaluated AZT against 67 industry peers in the Biotechnology industry. Both the profitability and the financial health of AZT get a neutral evaluation. Nothing too spectacular is happening here. AZT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

AZT had positive earnings in the past year.
In the past year AZT had a positive cash flow from operations.
AZT had positive earnings in each of the past 5 years.
Each year in the past 5 years AZT had a positive operating cash flow.
AZT.OL Yearly Net Income VS EBIT VS OCF VS FCFAZT.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

1.2 Ratios

The Return On Assets of AZT (0.64%) is better than 73.13% of its industry peers.
AZT's Return On Equity of 0.68% is fine compared to the rest of the industry. AZT outperforms 76.12% of its industry peers.
Industry RankSector Rank
ROA 0.64%
ROE 0.68%
ROIC N/A
ROA(3y)6.16%
ROA(5y)14.45%
ROE(3y)6.81%
ROE(5y)16.43%
ROIC(3y)N/A
ROIC(5y)N/A
AZT.OL Yearly ROA, ROE, ROICAZT.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40

1.3 Margins

AZT has a Profit Margin of 2.25%. This is in the better half of the industry: AZT outperforms 77.61% of its industry peers.
In the last couple of years the Profit Margin of AZT has declined.
With an excellent Gross Margin value of 94.33%, AZT belongs to the best of the industry, outperforming 94.03% of the companies in the same industry.
AZT's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 2.25%
GM 94.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-39.27%
PM growth 5YN/A
GM growth 3Y-0.94%
GM growth 5Y-0.64%
AZT.OL Yearly Profit, Operating, Gross MarginsAZT.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

6

2. Health

2.1 Basic Checks

AZT does not have a ROIC to compare to the WACC, probably because it is not profitable.
AZT has more shares outstanding than it did 1 year ago.
AZT has more shares outstanding than it did 5 years ago.
AZT has a better debt/assets ratio than last year.
AZT.OL Yearly Shares OutstandingAZT.OL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
AZT.OL Yearly Total Debt VS Total AssetsAZT.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 25.87 indicates that AZT is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 25.87, AZT belongs to the best of the industry, outperforming 94.03% of the companies in the same industry.
A Debt/Equity ratio of 0.02 indicates that AZT is not too dependend on debt financing.
AZT has a Debt to Equity ratio of 0.02. This is in the better half of the industry: AZT outperforms 77.61% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 25.87
ROIC/WACCN/A
WACC8.53%
AZT.OL Yearly LT Debt VS Equity VS FCFAZT.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 17.49 indicates that AZT has no problem at all paying its short term obligations.
The Current ratio of AZT (17.49) is better than 98.51% of its industry peers.
A Quick Ratio of 16.53 indicates that AZT has no problem at all paying its short term obligations.
AZT has a Quick ratio of 16.53. This is amongst the best in the industry. AZT outperforms 97.01% of its industry peers.
Industry RankSector Rank
Current Ratio 17.49
Quick Ratio 16.53
AZT.OL Yearly Current Assets VS Current LiabilitesAZT.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

6

3. Growth

3.1 Past

AZT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -93.94%.
The earnings per share for AZT have been decreasing by -43.42% on average. This is quite bad
Looking at the last year, AZT shows a very negative growth in Revenue. The Revenue has decreased by -17.09% in the last year.
The Revenue has been growing by 18.22% on average over the past years. This is quite good.
EPS 1Y (TTM)-93.94%
EPS 3Y-43.42%
EPS 5YN/A
EPS Q2Q%-200%
Revenue 1Y (TTM)-17.09%
Revenue growth 3Y-6.57%
Revenue growth 5Y18.22%
Sales Q2Q%-22.45%

3.2 Future

AZT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 63.87% yearly.
The Revenue is expected to grow by 30.65% on average over the next years. This is a very strong growth
EPS Next Y26.25%
EPS Next 2Y69.87%
EPS Next 3Y63.87%
EPS Next 5YN/A
Revenue Next Year8.45%
Revenue Next 2Y14.04%
Revenue Next 3Y15.71%
Revenue Next 5Y30.65%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AZT.OL Yearly Revenue VS EstimatesAZT.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
AZT.OL Yearly EPS VS EstimatesAZT.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 850.00 indicates a quite expensive valuation of AZT.
AZT's Price/Earnings ratio is a bit cheaper when compared to the industry. AZT is cheaper than 79.10% of the companies in the same industry.
AZT is valuated expensively when we compare the Price/Earnings ratio to 27.54, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 42.08, AZT can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AZT indicates a rather cheap valuation: AZT is cheaper than 83.58% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of AZT to the average of the S&P500 Index (36.44), we can say AZT is valued inline with the index average.
Industry RankSector Rank
PE 850
Fwd PE 42.08
AZT.OL Price Earnings VS Forward Price EarningsAZT.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 200 400 600 800

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AZT.OL Per share dataAZT.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates AZT does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as AZT's earnings are expected to grow with 63.87% in the coming years.
PEG (NY)32.38
PEG (5Y)N/A
EPS Next 2Y69.87%
EPS Next 3Y63.87%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AZT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARCTICZYMES TECHNOLOGIES ASA

OSL:AZT (7/21/2025, 4:13:26 PM)

17

+0.05 (+0.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-14 2025-08-14
Inst Owners15.83%
Inst Owner ChangeN/A
Ins Owners0.35%
Ins Owner ChangeN/A
Market Cap868.19M
Analysts76.67
Price Target19.38 (14%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)509.19%
Min EPS beat(2)-269.73%
Max EPS beat(2)1288.12%
EPS beat(4)1
Avg EPS beat(4)208.45%
Min EPS beat(4)-269.73%
Max EPS beat(4)1288.12%
EPS beat(8)3
Avg EPS beat(8)114.16%
EPS beat(12)3
Avg EPS beat(12)63.08%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-5.23%
Min Revenue beat(2)-13.1%
Max Revenue beat(2)2.64%
Revenue beat(4)1
Avg Revenue beat(4)-10.13%
Min Revenue beat(4)-18.99%
Max Revenue beat(4)2.64%
Revenue beat(8)2
Avg Revenue beat(8)-7.15%
Revenue beat(12)2
Avg Revenue beat(12)-7.23%
Revenue beat(16)5
Avg Revenue beat(16)-4.68%
PT rev (1m)5.56%
PT rev (3m)0%
EPS NQ rev (1m)-58.33%
EPS NQ rev (3m)-61.54%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.77%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.28%
Valuation
Industry RankSector Rank
PE 850
Fwd PE 42.08
P/S 8.89
P/FCF N/A
P/OCF 162.04
P/B 2.69
P/tB 3
EV/EBITDA N/A
EPS(TTM)0.02
EY0.12%
EPS(NY)0.4
Fwd EY2.38%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.1
OCFY0.62%
SpS1.91
BVpS6.31
TBVpS5.66
PEG (NY)32.38
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.64%
ROE 0.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 2.25%
GM 94.33%
FCFM N/A
ROA(3y)6.16%
ROA(5y)14.45%
ROE(3y)6.81%
ROE(5y)16.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-39.27%
PM growth 5YN/A
GM growth 3Y-0.94%
GM growth 5Y-0.64%
F-Score5
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 80.55%
Cap/Sales 6.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.49
Quick Ratio 16.53
Altman-Z 25.87
F-Score5
WACC8.53%
ROIC/WACCN/A
Cap/Depr(3y)231.16%
Cap/Depr(5y)215.23%
Cap/Sales(3y)11.45%
Cap/Sales(5y)9.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-93.94%
EPS 3Y-43.42%
EPS 5YN/A
EPS Q2Q%-200%
EPS Next Y26.25%
EPS Next 2Y69.87%
EPS Next 3Y63.87%
EPS Next 5YN/A
Revenue 1Y (TTM)-17.09%
Revenue growth 3Y-6.57%
Revenue growth 5Y18.22%
Sales Q2Q%-22.45%
Revenue Next Year8.45%
Revenue Next 2Y14.04%
Revenue Next 3Y15.71%
Revenue Next 5Y30.65%
EBIT growth 1Y-168.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year342.86%
EBIT Next 3Y124.31%
EBIT Next 5YN/A
FCF growth 1Y-102.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-84.71%
OCF growth 3Y-71.92%
OCF growth 5Y-16%